Stryker (NYSE: SYK) — 2Q26 Earnings Preview

Reports Thursday, July 30, 2026, after market close; Stryker plans to issue its release at approximately 4:05 p.m. ET and host its earnings call at 4:30 p.m. ET. (investors.stryker.com)

Bottom line

This is primarily a recovery-and-credibility quarter for Stryker. The central investor question is not whether underlying procedure demand remains healthy—management was emphatic after 1Q that it does—but whether Stryker can demonstrate that the March cybersecurity disruption was chiefly a timing issue rather than a hit to customer relationships, supply-chain reliability, or its 2026 earnings algorithm.

A clean 2Q result should show:

A meaningful normalization in organic growth, particularly from delayed Orthopaedics revenue recognition;
Confirmation that capital-product order books remain healthy despite the prior production interruption;
Better gross-margin trajectory following 1Q’s cyber-driven manufacturing under-absorption; and
Reaffirmed full-year guidance, with credible commentary around the balance of the cyber recovery in 2H.

The hurdle is meaningful. Published consensus is approximately $6.58 billion of revenue and $3.49 adjusted EPS, implying roughly 9.3% revenue growth and 11.5% adjusted-EPS growth versus 2Q25’s $6.02 billion and $3.13, respectively. (marketbeat.com)

What happened in 1Q—and why it frames 2Q

Stryker’s 1Q26 was heavily distorted by a cybersecurity incident identified on March 11, 2026. The company reported:

1Q26 result	Key takeaway
Organic sales growth: 2.4%	Well below the company’s normal growth profile, due to operational disruption and deferred revenue recognition.
Adjusted EPS: $2.60	Down 8.5% year over year.
Adjusted gross margin: 63.6%	Down 190 bps year over year, largely from lost manufacturing absorption and tariffs.
Adjusted operating margin: 21.1%	Down 180 bps year over year.
2026 outlook maintained	Organic growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10.

Management said that global manufacturing was fully operational again by early April, with commercial, ordering, and distribution systems restored. Importantly, the company maintained that hospital capital demand and procedure volumes remained sound, and that it had not seen a meaningful loss of customers.

However, recovery should be uneven:

Orthopaedics: A portion of cases continued because consigned inventory was already at hospitals, but revenue recognition was delayed; that creates the clearest opportunity for a 2Q catch-up.
MedSurg/Medical/Endoscopy: Recovery may be more back-half weighted because certain capital products are made to order and must be re-entered into production schedules.
Margins: The 1Q manufacturing disruption created an unusual fixed-cost absorption burden. Investors will want evidence that this pressure began to unwind in 2Q—not merely assurances that it will resolve later.

The guidance math matters

Stryker’s maintained full-year adjusted EPS range of $14.90–$15.10 remains the most important benchmark. After the $2.60 earned in 1Q and the current 2Q consensus of $3.49, the company would need approximately $8.81–$9.01 of adjusted EPS in 2H26 to reach the full-year range.

That is achievable given Stryker’s normal seasonal skew toward the second half, but it leaves limited room for additional execution setbacks. Thus, the market will likely focus more on the quality of reaffirmation—how management describes 3Q/4Q catch-up, margins, tariffs, and capital backlog—than on the headline 2Q EPS result alone.

Key items to watch on the release and call

1. Organic-growth recovery: is it broad-based?

The most important KPI is organic growth, especially given the 8.0%–9.5% full-year guide. A result near consensus revenue but supported only by foreign exchange, acquisitions, or deferred accounting would be less constructive than a broad-based organic rebound.

Specific segment markers:

Orthopaedics: Watch Knees, Hips, Trauma & Extremities, and the newly created Ortho Tech category. Underlying demand in these franchises remained solid in 1Q despite the disruption.
MedSurg & Neurotechnology: Investors should look for reacceleration in Instruments and Endoscopy, while recognizing that Medical’s capital-heavy revenue recovery may extend more into 3Q and 4Q.
International: International growth was disrupted but remains an important multi-year lever, especially as Stryker broadens access to Mako and launches products such as Pangea and LIFEPAK 35 across more markets.

2. Margin recovery versus tariff and cyber headwinds

In 1Q, the cyber event pressured gross margin through idle production time and lost manufacturing absorption. For 2Q, investors should assess:

Whether gross margin inflects positively sequentially;
Whether operational-excellence savings and price offset tariff and input-cost pressure;
Whether Stryker still expects approximately the same full-year margin-expansion framework discussed in 1Q; and
Whether cyber-remediation spending or incremental security investments change free-cash-flow conversion expectations.

A margin improvement without a corresponding recovery in organic demand would be less compelling; the preferred outcome is growth recovery plus visible factory absorption normalization.

3. The Mako and Ortho Tech growth engine

Mako remains a central part of the Stryker growth story. Management described a record 1Q for Mako installations in both the U.S. and international markets, with high utilization rates. The key 2Q topics are:

Demand and installation cadence for Mako 4;
Commercial rollout of Mako Shoulder on Mako 4;
Early uptake of Mako RPS, Stryker’s handheld robotic solution;
The contribution from Triathlon Gold in knees; and
Whether Ortho Tech is succeeding in combining Mako, enabling technology, power tools, and related consumables into a more cohesive customer offering.

The strategic point: Mako’s value is increasingly tied not just to capital placements, but to procedure pull-through, implant share, recurring consumables, service, and future applications.

4. MedSurg capital recovery and product-cycle durability

Management previously indicated that the recovery for more capital-intensive MedSurg businesses could be weighted toward the back half of the year. Accordingly, investors should ask whether:

The capital backlog remains elevated;
Delayed orders are being rescheduled as expected;
LIFEPAK 35 production and shipments have normalized;
Pangea continues to drive Trauma growth, including international expansion; and
SmartCare/Smart Hospital—integrating Vocera, care.ai, and Stryker beds—has gained early commercial traction.

5. Vascular strategy: Inari integration and AVS

The peripheral vascular expansion is increasingly relevant to the longer-term multiple and growth profile:

Inari is now past much of its sales-force transition and integration work. Management has characterized underlying procedural demand as healthy and sees international commercialization as an underdeveloped opportunity.
Stryker acquired Amplitude Vascular Systems (AVS) in May for approximately $435 million upfront plus potential milestones. AVS adds an intravascular lithotripsy platform for peripheral arterial disease, reinforcing Stryker’s intent to build a broader vascular franchise.

Investors will look for any update on commercial timing, integration, expected dilution, and how quickly Stryker can leverage the Inari call point.

Why the stock may be set up for a more binary reaction

SYK closed at $350.69 on July 29, 2026—essentially flat versus its December 31, 2025 close, but up about 24% from its May 11 low and about 11% from the late-April post-1Q trough.

That recovery suggests investors have already become more comfortable that the cyber disruption was transitory. As a result:

Upside case: Strong organic-growth rebound, improving margins, and confident full-year guidance commentary could validate that view and support further multiple recovery.
Downside case: A modest beat paired with cautious commentary on delayed capital shipments, cyber costs, tariffs, or 2H recovery timing could be viewed negatively because the stock has already retraced much of the immediate post-incident decline.

Bull case

The 1Q disruption was mostly a deferral, with 2Q proving the underlying 8%–10% organic-growth algorithm remains intact.
Mako, Pangea, LIFEPAK 35, endoscopy, and neurotechnology product cycles sustain above-market growth.
Margins recover quickly as manufacturing utilization normalizes and operational-excellence initiatives offset tariffs.
Inari stabilizes and AVS expands the addressable vascular opportunity.
Full-year guidance is reaffirmed with enough confidence to reopen the possibility of an eventual raise.

Bear case

Deferred revenue catches up more slowly than expected, especially in capital-heavy MedSurg franchises.
Cyber-related disruption proves more costly or operationally persistent than management has indicated.
Tariffs, input costs, and higher interest expense constrain incremental margins.
Growth is uneven across Orthopaedics, with Mako placements or joint-replacement utilization less robust than expected.
Guidance is maintained but accompanied by more explicit back-half dependence, reducing confidence in the implied 2H EPS ramp.

Investor takeaway

The key read-through is execution, not simply the EPS print. For Stryker to work after this report, investors likely need confirmation that 1Q was an isolated operational shock and that the company is back to delivering high-single-digit-to-low-double-digit organic growth with recovering margins.

The highest-value disclosures will be:

Organic sales growth by major business;
Evidence of delayed-sales recovery;
Gross-margin and operating-margin progression;
Full-year guide confidence and implied 2H cadence;
Mako installation/utilization commentary; and
Updates on Inari/AVS and capital-market demand.

Research basis

Stryker 1Q26 Form 10-Q and 1Q26 earnings-call transcript
Stryker 2Q25 earnings-call transcript
Stryker 2Q26 earnings-date announcement and event materials
Published consensus data as of July 29, 2026. (investors.stryker.com)